Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $45.00 price objective on the stock. HC Wainwright's target price would indicate a potential upside of 215.79% from the stock's current price.

Several other research analysts have also issued reports on ORKA. BTIG Research started coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating for the company. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd. Finally, Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Monday, July 21st. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has an average rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Stock Performance

Shares of ORKA traded up $0.02 during mid-day trading on Wednesday, hitting $14.25. The company's stock had a trading volume of 70,223 shares, compared to its average volume of 362,029. Oruka Therapeutics has a one year low of $5.49 and a one year high of $52.32. The firm has a market capitalization of $533.52 million, a PE ratio of -3.16 and a beta of -0.34. The stock's 50-day moving average is $12.52 and its two-hundred day moving average is $11.49.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. Analysts expect that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new position in Oruka Therapeutics during the fourth quarter worth about $54,000. Squarepoint Ops LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter valued at about $236,000. Charles Schwab Investment Management Inc. bought a new position in shares of Oruka Therapeutics during the 4th quarter valued at about $303,000. AlphaQuest LLC bought a new position in shares of Oruka Therapeutics during the 1st quarter valued at about $168,000. Finally, Jane Street Group LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter valued at about $343,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.